When to stop GnRH analog therapy: The experience of the italian study group for physiopathology of puberty

T. Arrigo, M. Cisternino, F. Galluzzi, S. Bertelloni, A. M. Pasquino, F. Antoniazzi, P. Borrelli, G. Crisafulli, M. Wasniewska, F. De Luca

Research output: Contribution to journalArticle

Abstract

Data reported in this study have been recently published elsewhere. The authors retrospectively analyzed the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP), who had been treated with the same therapy protocol (Decapeptyl Depot at the dose of 60 μg/kg i.m. every 28 days) for at least 2 years (since 7.0 ± 1.3 yr) and followed until puberty was completed and FH was reached. During the entire treatment period we observed: A) a decrease of height standard deviation scores (SDS) (from 1.5±1.7 to 0.9±1.3 SDS, p

Original languageEnglish
Pages (from-to)759-764
Number of pages6
JournalJournal of Pediatric Endocrinology and Metabolism
Volume13
Issue numberSUPPL. 1
Publication statusPublished - 2000

Fingerprint

Puberty
Gonadotropin-Releasing Hormone
Triptorelin Pamoate
Therapeutics

Keywords

  • Central precocious puberty
  • Final height
  • Gonadotropin releasing hormone agonists
  • Idiopathic early puberty

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Arrigo, T., Cisternino, M., Galluzzi, F., Bertelloni, S., Pasquino, A. M., Antoniazzi, F., ... De Luca, F. (2000). When to stop GnRH analog therapy: The experience of the italian study group for physiopathology of puberty. Journal of Pediatric Endocrinology and Metabolism, 13(SUPPL. 1), 759-764.

When to stop GnRH analog therapy : The experience of the italian study group for physiopathology of puberty. / Arrigo, T.; Cisternino, M.; Galluzzi, F.; Bertelloni, S.; Pasquino, A. M.; Antoniazzi, F.; Borrelli, P.; Crisafulli, G.; Wasniewska, M.; De Luca, F.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 13, No. SUPPL. 1, 2000, p. 759-764.

Research output: Contribution to journalArticle

Arrigo, T, Cisternino, M, Galluzzi, F, Bertelloni, S, Pasquino, AM, Antoniazzi, F, Borrelli, P, Crisafulli, G, Wasniewska, M & De Luca, F 2000, 'When to stop GnRH analog therapy: The experience of the italian study group for physiopathology of puberty', Journal of Pediatric Endocrinology and Metabolism, vol. 13, no. SUPPL. 1, pp. 759-764.
Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F et al. When to stop GnRH analog therapy: The experience of the italian study group for physiopathology of puberty. Journal of Pediatric Endocrinology and Metabolism. 2000;13(SUPPL. 1):759-764.
Arrigo, T. ; Cisternino, M. ; Galluzzi, F. ; Bertelloni, S. ; Pasquino, A. M. ; Antoniazzi, F. ; Borrelli, P. ; Crisafulli, G. ; Wasniewska, M. ; De Luca, F. / When to stop GnRH analog therapy : The experience of the italian study group for physiopathology of puberty. In: Journal of Pediatric Endocrinology and Metabolism. 2000 ; Vol. 13, No. SUPPL. 1. pp. 759-764.
@article{f0bd6cde9388421d833c364f35a999d5,
title = "When to stop GnRH analog therapy: The experience of the italian study group for physiopathology of puberty",
abstract = "Data reported in this study have been recently published elsewhere. The authors retrospectively analyzed the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP), who had been treated with the same therapy protocol (Decapeptyl Depot at the dose of 60 μg/kg i.m. every 28 days) for at least 2 years (since 7.0 ± 1.3 yr) and followed until puberty was completed and FH was reached. During the entire treatment period we observed: A) a decrease of height standard deviation scores (SDS) (from 1.5±1.7 to 0.9±1.3 SDS, p",
keywords = "Central precocious puberty, Final height, Gonadotropin releasing hormone agonists, Idiopathic early puberty",
author = "T. Arrigo and M. Cisternino and F. Galluzzi and S. Bertelloni and Pasquino, {A. M.} and F. Antoniazzi and P. Borrelli and G. Crisafulli and M. Wasniewska and {De Luca}, F.",
year = "2000",
language = "English",
volume = "13",
pages = "759--764",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - When to stop GnRH analog therapy

T2 - The experience of the italian study group for physiopathology of puberty

AU - Arrigo, T.

AU - Cisternino, M.

AU - Galluzzi, F.

AU - Bertelloni, S.

AU - Pasquino, A. M.

AU - Antoniazzi, F.

AU - Borrelli, P.

AU - Crisafulli, G.

AU - Wasniewska, M.

AU - De Luca, F.

PY - 2000

Y1 - 2000

N2 - Data reported in this study have been recently published elsewhere. The authors retrospectively analyzed the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP), who had been treated with the same therapy protocol (Decapeptyl Depot at the dose of 60 μg/kg i.m. every 28 days) for at least 2 years (since 7.0 ± 1.3 yr) and followed until puberty was completed and FH was reached. During the entire treatment period we observed: A) a decrease of height standard deviation scores (SDS) (from 1.5±1.7 to 0.9±1.3 SDS, p

AB - Data reported in this study have been recently published elsewhere. The authors retrospectively analyzed the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP), who had been treated with the same therapy protocol (Decapeptyl Depot at the dose of 60 μg/kg i.m. every 28 days) for at least 2 years (since 7.0 ± 1.3 yr) and followed until puberty was completed and FH was reached. During the entire treatment period we observed: A) a decrease of height standard deviation scores (SDS) (from 1.5±1.7 to 0.9±1.3 SDS, p

KW - Central precocious puberty

KW - Final height

KW - Gonadotropin releasing hormone agonists

KW - Idiopathic early puberty

UR - http://www.scopus.com/inward/record.url?scp=0033857746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033857746&partnerID=8YFLogxK

M3 - Article

C2 - 10969918

AN - SCOPUS:0033857746

VL - 13

SP - 759

EP - 764

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - SUPPL. 1

ER -